


SYNTHESIS

HADRON THERAPY IN CHILDREN

AN UPDATE OF THE SCIENTIFIC EVIDENCE FOR 15 PAEDIATRIC CANCERS





Belgian Health Care Knowledge Centre

The Belgian Health Care Knowledge Centre (KCE) is an organization of public interest, created on the 24th of December 2002 under the supervision of the Minister of Public Health and Social Affairs. KCE is in charge of conducting studies that support the political decision making on health care and health insurance.

Executive Board

	<i>Actual Members</i>	<i>Substitute Members</i>
President	Pierre Gillet	
CEO - National Institute for Health and Disability Insurance (vice president)	Jo De Cock	Benoît Collin
President of the Federal Public Service Health, Food Chain Safety and Environment (vice president)	Dirk Cuypers	Christiaan Decoster
President of the Federal Public Service Social Security (vice president)	Frank Van Massenhove	Jan Bertels
General Administrator of the Federal Agency for Medicines and Health Products	Xavier De Cuyper	Greet Musch
Representatives of the Minister of Public Health	Brieuc Van Damme Ri De Ridder	Koen Vandewoude Yolande Avontroodt
Representatives of the Minister of Social Affairs	Bert Winnen Johan De Haes	Magali Pirson Dirk Ramaekers
Representatives of the Council of Ministers	Jean-Noël Godin Marc Loix	Natacha Beugnier Tijs Neutens
Intermutualistic Agency	Michiel Callens Patrick Verertbruggen	Frank De Smet Jean-Marc Laasmans
Professional Organisations - representatives of physicians	Xavier Brenez Marc Moens	Geert Messiaen Roland Lemye
Professional Organisations - representatives of nurses	Jean-Pierre Baeyens Ellen De Wandeler	Rita Cuypers Ludo Meyers
Hospital Federations	Myriam Hubinon Johan Pauwels	Olivier Thonon Katrien Kesteloot
Social Partners	Jean-Claude Praet Rita Thys	Pierre Smiets Catherine Rutten
House of Representatives	Paul Palsterman <i>To be assigned</i>	Celien Van Moerkerke



Control

Government commissioner

Steven Sterckx

Management

General director
Deputy general director
Program Management

Raf Mertens
Christian Léonard
Kristel De Gauquier
Dominique Paulus

Contact

Belgian Health Care Knowledge Centre (KCE)
Doorbuilding (10th Floor)
Boulevard du Jardin Botanique, 55
B-1000 Brussels
Belgium

T +32 [0]2 287 33 88

F +32 [0]2 287 33 85

info@kce.fgov.be

<http://www.kce.fgov.be>

SYNTHESIS

HADRON THERAPY IN CHILDREN

AN UPDATE OF THE SCIENTIFIC EVIDENCE FOR 15 PAEDIATRIC CANCERS

ROOS LEROY, NADIA BENAHMED, FRANK HULSTAERT, FRANÇOISE MAMBOURG, NICOLAS FAIRON, LIESBET VAN EYCKEN, DIRK DE RUYSSCHER



COLOPHON

Title:	Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers – Synthesis
Authors:	Roos Leroy (KCE), Nadia Benahmed (KCE), Frank Hulstaert (KCE), Françoise Mambourg (KCE), Nicolas Fairon (KCE), Liesbet Van Eycken (Stichting Kankerregister – Fondation Registre du Cancer), Dirk De Ruyscher (KU Leuven)
Project coordinator:	Marijke Eyssen (KCE)
Reviewers:	Raf Mertens (KCE), Sabine Stordeur (KCE), Geneviève Veereman (KCE)
External experts:	Edward Baert (UGent), Yves Benoit (UGent), Sylviane Carbonnelle (AFCN – FANC), Olivier de Witte (Erasmus; ULB), Bart Depreitere (KU Leuven), Lorraine Donnay (Clinique & Maternité Sainte-Elisabeth, Namur), Hilde Engels (RIZIV – INAMI), Nancy Van Damme (Stichting Kankerregister – Fondation Registre du Cancer), Paul Van Houtte (Institut Jules Bordet; ULB), Claudia Wild (Ludwig Boltzmann Institute, Austria)
External validators:	Gudrun Goitein (Since September 2014 retired from Paul Scherrer Institute, Villigen, Switzerland), Edward C. Halperin (New York Medical Centre, US), Stefaan Van Gool (KU Leuven)
Acknowledgements:	Kris Henau (Stichting Kankerregister – Fondation Registre du Cancer), Mattias Neyt (KCE), Jo Robays (KCE), Chris Segaeert (RIZIV – INAMI), Beate Timmerman (Westdeutsches Protonentherapiezentrum Essen, Germany), Leen Verleye (KCE)
Other reported interests:	None declared
Layout:	Ine Verhulst
Coverpictures:	The left cover image is copyrighted by Sage Publications, Inc. The right cover image is copyrighted by Eric Bouvet / Institut Curie (ref. 4487)

Disclaimer:

- **The external experts were consulted about a (preliminary) version of the scientific report. Their comments were discussed during meetings. They did not co-author the scientific report and did not necessarily agree with its content.**
- **Subsequently, a (final) version was submitted to the validators. The validation of the report results from a consensus or a voting process between the validators. The validators did not co-author the scientific report and did not necessarily all three agree with its content.**
- **Finally, this report has been approved by a majority of votes by the Executive Board.**
- **Only the KCE is responsible for errors or omissions that could persist. The policy recommendations are also under the full responsibility of the KCE.**



Publication date: 08 January 2015
Domain: Health Technology Assessment (HTA)
MeSH: Proton therapy; Heavy ions; Radiotherapy; Review [Publication type]
NLM Classification: WN 250.5.P7
Language: English
Format: Adobe® PDF™ (A4)
Legal depot: D/2015/10.273/03

Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence
<http://kce.fgov.be/content/about-copyrights-for-kce-reports>.



How to refer to this document?

Leroy R, Benahmed N, Hulstaert F, Mambourg F, Fairon N, Van Eycken L, De Ruyscher D. Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers – Synthesis. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). 2015. KCE Reports 235Cs. D/2015/10.273/03.

This document is available on the website of the Belgian Health Care Knowledge Centre.



■ FOREWORD

If there is one area in health care that is emotionally difficult, it is paediatric oncology. The sight of a child suffering - of a dying child - is not only unbearable, it also evokes a feeling of rebelliousness, an appeal to do everything within our capabilities to save this child. And then there is this high-tech radiation technique, which promises to offer just that little bit extra. A form of radiation that is at least equally effective against the tumour, but clearly causes less collateral damage to the surrounding tissues and therefore should also cause fewer secondary tumours induced by the radiation itself. The physical models are convincing, the simulations are promising and the clinical experience appears to be positive.

The stakes are high in every respect, not only because this is about children with cancer. The price tag for a new proton centre can easily exceed 30 million Euros and the running costs are similarly high. Understandably, those who have set out on this path defend their case through thick and thin; and they are determined to conquer a place for this innovative technique in the health care landscape. From experience we know that this type of hi-tech innovations cannot be stopped anyway, and recent history seems to confirm this also for hadron centres.

It is a downright shame that - even after enormous global investments and at least 120,000 patients treated - there is still virtually no conclusive evidence to support the superiority of this technique in children. Whilst good international, multi-centre studies could quickly provide the required insights for a fraction of the investment costs, the centres and their protagonists mainly continue to act as rival SMEs who compete for patients. And one does not need to look to the suppliers of this heavy infrastructure for support for this type of studies.

So, in response to the question posed to us by the National Institute of Health and Disability Insurance (RIZIV – INAMI) whether there is now more evidence to support the reimbursed paediatric indications - the answer sadly remains “no”. Whilst awaiting the results of the few studies that are ongoing, there is probably little choice other than to give these young patients the benefit of the doubt, but without any guarantee that the result will eventually be positive. This is and remains too little, too late.

Christian LÉONARD
Deputy general director

Raf MERTENS
General director



■ SUMMARY

1 INTRODUCTION

Anno 2014 there are no hadron facilities in Belgium; Belgian citizens eligible for hadron therapy (i.e. proton beam therapy (PBT) or carbon ion radiotherapy (CIRT)) are sent abroad. From September 2014 on (and until the end of September 2017), the costs related to hadron therapy (i.e. the treatment, transport and accommodation) are reimbursed if the diagnosis is on the list of eligible indications^a and if the “Agreement Council for Hadron Therapy” (akkoordraad/ conseil d'accord) approves the application.

The objective of this study was to evaluate the clinical effectiveness of proton beam (or carbon ion) therapy in those indications in children currently reimbursed by the National Institute for Health and Disability Insurance (RIZIV – INAMI). It concerns the following 16 indications:

Proton beam therapy

- Skull base chondrosarcoma
- Skull base & (para)spinal chordoma
- Craniopharyngioma
- Ependymoma
- Esthesioneuroblastoma
- Ewing sarcoma
- CNS germinoma
- Low-grade glioma (incl. optic pathway)
- Medulloblastoma / primitive neuroectodermal tumours (PNET)
- Non-resectable osteosarcoma
- Pelvic sarcoma
- Pineal parenchymal tumours (not pineoblastoma)
- Retinoblastoma
- Rhabdomyosarcoma
- (Para)spinal ‘adult type’ soft tissue sarcoma

^a

<http://www.riziv.fgov.be/nl/professionals/verzorgingsinstellingen/ziekenhuize>

<n/zorg/Paginas/Hadron-english.aspx>; for osteosarcoma PBT & CIRT are considered, leading to 16 indications in 15 cancers.



Carbon ion radiotherapy

- Non-resectable or incompletely resected high-grade osteosarcoma with or without metastases

2 METHODS

A systematic search for relevant publications was carried out in Medline, EMBASE, and the Cochrane Library. Reviews and primary studies on proton beam therapy and/or carbon ion therapy published between 2007 (i.e. end date of search strategy of previous KCE Hadron HTA¹) up to March 2014 were searched. An overview of the inclusion and exclusion criteria, the search strategy and the flow chart of the selection process are provided in the Supplement. A final update of the search (restricted to Medline) was performed on September 11, 2014.

3 RESULTS

After selection, we retrieved 21 primary studies on the 16 potential indications under study. On top of the non-randomized, non-controlled and retrospective nature of the majority of retrieved studies - with the limitations characteristic of these types of studies (e.g. selection bias, recall bias) - all studies suffered from very serious methodological limitations (among others small sample size, long enrolment period, no clear inclusion nor exclusion criteria, variable treatment schemes, short follow-up, no information on the methods and intervals of follow-up, complications only assessed in a subset of patients) and hence when GRADE² was applied, the level of scientific evidence for all outcomes in all indications was very low.

- For retinoblastoma there is very low level scientific evidence that PBT results in a lower risk of developing RT-induced in-field secondary malignancies. However, since radiation-induced solid malignancies need at least five to ten years to develop and for some children in the study the follow-up was short, the results should be interpreted with caution.
- For craniopharyngioma there is very low level scientific evidence that PBT compared with intensity modulated radiotherapy (IMRT) did not result in significant differences in overall survival, cystic failure-free survival, nodular failure-free survival, toxicity or cyst dynamics.

- For chondrosarcoma, chordoma, ependymoma, esthesioneuroblastoma, Ewing sarcoma, CNS germinoma, glioma, medulloblastoma, non-resectable osteosarcoma (for PBT as well as CIRT) and rhabdomyosarcoma there is insufficient scientific evidence to support or to refute the use of PBT (or CIRT) in children.
- For pelvic sarcoma, pineal parenchymal tumour, PNET and (para-)spinal “adult type” soft tissue sarcoma there is no scientific evidence to support or to refute the use of PBT in children.

Based on the 2004-2011 data provided by the Belgian Cancer Registry, it can be estimated that in Belgium 37 children (0-14 y.o.) and 14 adolescents (15-19 y.o.) may be eligible for radiotherapy/proton beam therapy on a yearly basis.

4 CONCLUSIONS

Although there is no doubt that proton therapy reduces the radiation dose to normal tissues and organs, to date clinical data on PBT in all paediatric cancers under study is lacking critical information on measures of long-term effectiveness and harm. Prospective comparative clinical trials in the field are urgently needed.



■ SYNTHESIS

1	INTRODUCTION	2
2	METHODS	3
3	RESULTS	3
4	CONCLUSIONS	3
5	INTRODUCTION	5
5.1	RATIONALE & RESEARCH QUESTIONS	5
5.2	WHAT IS HADRON THERAPY?.....	5
	5.2.1 Proton beam therapy.....	6
	5.2.2 Carbon ion radiotherapy.....	7
5.3	WHY PROTON BEAM THERAPY IN CHILDREN?	7
5.4	PROTON BEAM THERAPY – THE HOLY GRAIL IN PAEDIATRIC RADIATION ONCOLOGY?	7
6	SYSTEMATIC LITERATURE REVIEW	8
6.1	CLINICAL EFFECTIVENESS OF PROTON BEAM THERAPY AND ELIGIBILITY FOR RADIOTHERAPY/PROTON BEAM THERAPY BY TUMOUR TYPE	8
	6.1.1 Skull base chondrosarcoma.....	8
	6.1.2 Skull base & (para)spinal chordoma	9
	6.1.3 Craniopharyngioma.....	9
	6.1.4 Ependymoma	10
	6.1.5 Esthesioneuroblastoma.....	10
	6.1.6 Ewing sarcoma.....	11
	6.1.7 CNS germinoma.....	11
	6.1.8 Low-grade glioma (incl. optic pathway).....	12
	6.1.9 Medulloblastoma / primitive neuroectodermal tumours	12
	6.1.10 Non-resectable osteosarcoma	13
	6.1.11 Pelvic sarcomas	13
	6.1.12 Pineal parenchymal tumours	13
	6.1.13 Retinoblastoma	14
	6.1.14 Rhabdomyosarcoma	15



6.1.15 (Para-)spinal ‘adult type’ soft tissue sarcoma (STS).....15

6.2 CLINICAL EFFECTIVENESS OF CARBON ION RADIOTHERAPY AND ELIGIBILITY FOR
RADIOTHERAPY/CARBON ION RADIOTHERAPY16

Non-resectable osteosarcoma16

7 DISCUSSION16

8 KEY MESSAGES.....17

LIST OF FIGURES

Figure 1 – Radiation dose profiles: photons vs. protons6

Figure 2 – Passive scattering vs. pencil beam (active) scanning.....7



LIST OF ABBREVIATIONS & ACRONYMS

ABBREVIATION	DEFINITION
BCR	Belgian cancer registry
CFFS	Cystic failure-free survival
CIRT	Carbon ion radiotherapy
CNS	Central Nervous System
CSI	Craniospinal irradiation
DNA	Deoxyribonucleic acid
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HTA	Health technology assessment
IMRT	Intensity modulated radiotherapy
Incl.	Including
KCE	Belgian Health Care Knowledge Centre
MOC/COM	Multidisciplinary oncological consultation
NFFS	Nodular failure-free survival
OAR	Organs at risk
OS	Overall survival
PBT	Proton beam therapy
PNET	Primitive neuroectodermal tumours
RBE	Relative biological effectiveness
RIZIV-INAMI	National Institute for Health and Disability Insurance (Rijksinstituut voor Ziekte- en Invaliditeitsverzekering - Institut National d'Assurance Maladie-Invalidité)
RT	Radiotherapy
SEER	Surveillance, Epidemiology and End Results (database)
SOBP	Spread Out Bragg peak
STS	Soft tissue sarcomas
y.o.	Years old



1 INTRODUCTION

1.1 Rationale & research questions

Anno 2014 there are no hadron facilities in Belgium; Belgian citizens eligible for hadron therapy are sent abroad. From September 2014 on (and until the end of September 2017), the costs related to hadron therapy (i.e. the treatment, transport and accommodation) are reimbursed through a specially earmarked budget of € 3.6 million per year (an amount that is index-linked). A list of eligible indications for children (and adults) has been defined^b; this list was based on the Feasibility study of a Hadron Therapy Centre in Belgium (2013)³. The “Agreement Council for Hadron Therapy” (Akkoordraad voor de begeleiding van hadrontherapie/Conseil d'accord pour l'accompagnement de l'hadronthérapie) evaluates every application and decides whether the treatment is reimbursed.

The objective of this study was to evaluate the clinical effectiveness of proton beam (or carbon ion) therapy in the 16 indications in children currently reimbursed by the National Institute for Health and Disability Insurance (RIZIV – INAMI). It concerns the following indications:

Proton beam therapy

- Skull base chondrosarcoma
- Skull base & (para)spinal chordoma
- Craniopharyngioma
- Ependymoma
- Esthesioneuroblastoma
- Ewing sarcoma
- CNS germinoma
- Low-grade glioma (incl. optic pathway)
- Medulloblastoma / Primitive neuroectodermal tumours (PNET)
- Non-resectable osteosarcoma
- Pelvic sarcoma
- Pineal parenchymal tumours (not pineoblastoma)
- Retinoblastoma
- Rhabdomyosarcoma
- (Para)spinal ‘adult type’ soft tissue sarcoma

Carbon ion radiotherapy

- Non-resectable or incompletely resected high-grade osteosarcoma with or without metastases

1.2 What is hadron therapy?

Hadron therapy or charged particle radiation therapy uses beams of protons or other charged particles, such as carbon, helium, neon, or silicon. At present **only protons and carbon ions** are in clinical use⁴. Worldwide, more than 120 000 patients have been treated with particle therapy since 1954: more than 13 000 with carbon ions and more than 105 000 with proton therapy⁴. Proton beam therapy in children has only been introduced a couple of decades ago; in the US, paediatric patients comprised 13% of all patients treated with PBT in 2012⁵.

Photon radiation (i.e. conventional radiotherapy) deposits most of its energy below the skin surface and in normal tissue going in (‘proximal dose’), hits the target site (the tumour) and still deposits energy and thus affects normal tissues when coming out past the target (‘distal dose’) (Figure 1). In contrast, charged particles deposit a low dose near the surface and a large fraction of their energy at or around the target, at the end of the range of beam penetration. Tissues beyond the tumour location receive very little of the dose. This peak energy delivery is known as the **Bragg Peak** (Figure 1)⁶. The absence of radiation distal to the target is one of the major advantages of proton radiotherapy, allowing for substantial tissue sparing.


By adjusting the energy of the charged particles and the intensity of the beam, one can deliver pre-specified doses anywhere in the body with high precision⁷. In this way the proton beam can be adjusted to match the depth and extent of the target volume and excellent conformity can be achieved. Because the Bragg peak of a mono-energetic proton beam is narrow, several beams with closely spaced penetration depths are used to treat the entirety of the tumour. This area of uniform dose over the entirety of the tumour is termed a **Spread Out Bragg Peak (SOBP)** (Figure 1). While the SOBP does increase dose deposition proximal to the tumour, the entrance dose usually remains substantially lower than that of photon radiotherapy⁸.

^b <http://www.riziv.fgov.be/nl/professionals/verzorgingsinstellingen/ziekenhuizen/zorg/Paginas/Hadron-english.aspx>; for osteosarcoma PBT & CIRT are considered, leading to 16 indications in 15 cancers.



Because charged particles damage cell DNA in qualitatively different ways than photons, the same amount of physical radiation can have much more pronounced biological effects, resulting in larger cellular damage⁷. The **relative biological effectiveness** (RBE) is defined as the ratio of a dose of photons to a dose of any particle to produce the same biological effect. The RBE of protons is approximately 1.1, indicating that protons result in approximately 10% more biological damage per unit dose than photons⁷. Carbon ions have a similar RBE to protons along the particle path but have a markedly increased RBE (estimated at 3-4) at their maximum depth of penetration. As a result, the deleterious effects on normal tissues proximal to the tumour are expected to be similar to proton radiotherapy, while tumour killing is enhanced at maximum depth⁸.

Figure 1 – Radiation dose profiles: photons vs. protons



[Figure – Source: Cotter et al., 2012 p269⁸ - traduction]

1.2.1 Proton beam therapy

The protons emerging from a cyclotron or synchrotron form a narrow pencil beam; in order to cover a treatment field of the size of a tumour and hence produce a Spread Out Bragg Peak, the pencil beam either scans the target or is scattered by a foil. Currently, both passive scattering and active scanning beam delivery systems are in use.

Passive scattering technique (or scatter foil technique)

Passive scattering is currently the most common proton beam technique employed^{8, 9}. A proton beam hits the scatter foil and is spread laterally (Figure 2). The beam is further shaped via brass apertures and compensators to conform to the distal edge of the tumour⁸. There are several *disadvantages* associated with the passive scattering technique; the most important is the production of **secondary neutrons**, which may induce secondary malignancies⁹⁻¹¹. It is estimated that these external neutrons deliver a total-body equivalent dose that is even larger than the leakage radiation from conventional linear accelerators¹². Yet, the passive scattering technique may be indicated in those cases where the target has a regular, not too complex shape (G.Goitein, personal communication).

Active scanning technique

There are two types:

Spot-scanning or pencil beam scanning

Only a couple of centres worldwide use this technique where magnets steer a small pencil beam of protons to specific positions within a tumour target without the need for brass apertures or compensators (Figure 2)⁸. The pencil beam technology has two main *advantages* over the passive scattering technique. First, it allows for decreasing the entry dose while avoiding an exit dose. Second, the neutron scatter is reduced significantly, an advantage that is particularly important for the paediatric patient^{8, 9}. Yet, pencil beam is *more sensitive* to any misalignment or density change.


Uniform beam scanning

This technique uses a range modulator, patient collimator and range compensator similar to the passive scattering technique, but it utilizes magnets instead of scattering foils to spread the beam laterally¹³. With this system, the beams are scanned in a fixed pattern with a uniform intensity for each layer, while in the pencil beam scanning system, beams are scanned



with variable intensity and pattern¹⁴. Overall, the uniform scanning system uses less material in the beam path compared to the passive delivery system and therefore is supposed to produce fewer neutrons¹³.

Figure 2 – Passive scattering vs. pencil beam (active) scanning



[Figure – Source: Hall 2006 p6¹²]

1.2.2 Carbon ion radiotherapy

As carbon ion radiotherapy is hardly used in children and there was only one research question on carbon ion radiotherapy, the interested reader is referred to the Scientific Report for more background information.

1.3 Why proton beam therapy in children?

In paediatric radiation oncology, the ultimate goal is to treat the disease while limiting as much as possible the (acute and late) effects of radiation on growth and development, cognition, neuroendocrine function and last but certainly not least the induction of secondary tumours. The age of the

paediatric patient plays a major role in the design of the treatment plan. New developments aim at avoiding and/or postponing radiotherapy in children, e.g. by altering the chemotherapy regimen. Reducing the exposure of normal tissues to therapeutic radiation would presumably decrease the risk of subsequent malignancies and other radiation-induced side effects¹⁵. Here, the option of hadron therapy, particularly proton beam therapy, comes in.

Essentially, there are two rationales for using proton beam therapy: the dose to organs at risk can be reduced and/ or the risk for second malignancies can be lowered, and second, the dose to the tumour can be increased without putting the organs at risk to a higher dose (dose escalation). Although the latter is appealing, dose-escalation and hypofractionation are experimental approaches that should be restricted to clinical trials.

1.4 Proton beam therapy – the Holy Grail in paediatric radiation oncology?

Despite the thorough physical underpinning of proton beam therapy showing a **reduction of the radiation dose** to normal tissues and organs, several systematic reviews on the clinical effectiveness of PBT clearly stated that for most clinical indications, it still **cannot be concluded that proton beams are clinically truly superior** to photon therapy^{1, 16-19}. It remains unproven in the clinic whether protons are more suitable when OAR dose constraints limit the delivery of the most appropriate tumour X-ray radiotherapy doses¹⁹. Nor is it known whether proton therapy allows radiation dose escalation without increasing side effects¹⁹.

What's more, the clinical application of proton beams still suffers from **several technical limitations and disadvantages**, which are elaborated in the Scientific Report. One of the most critical concerns is the production of **secondary neutrons** with the passive scattering technique as even low neutron doses have a high potential for carcinogenesis²⁰. This is extremely important, in particular because the reduction of secondary cancer risk is in fact one of the principal reasons for the move from photon towards proton beam therapy in children.



2 SYSTEMATIC LITERATURE REVIEW

A systematic search for relevant publications was done in Medline (through OVID), EMBASE, and the Cochrane Library. Reviews and primary studies on proton beam therapy and/or carbon ion therapy published between 2007 (i.e. end date of the search strategy of the previous KCE Hadron HTA¹) up to March 2014 were searched. An overview of the inclusion and exclusion criteria, the search strategy and the flow chart of the selection process are given in the Supplement. A final update of the search (restricted to Medline through OVID) was performed on September 11, 2014.

After selection, we retrieved **21 primary studies** on the 16 potential indications under study. On top of the non-randomized, non-controlled and retrospective nature of the majority of retrieved studies - with the limitations characteristic of these types of studies (e.g. selection bias, recall bias) - all studies suffered from very serious methodological limitations (among others small sample size, long enrolment period, variable treatment schemes, short follow-up, complications only assessed in a subset of patients) and hence when GRADE² was applied, the **level of scientific evidence for all outcomes in all indications was very low.**

2.1 Clinical effectiveness of proton beam therapy and eligibility for radiotherapy/proton beam therapy by tumour type

In the subsequent sections, eligibility for radiotherapy/proton beam therapy (RT/PBT) is based on the report of the multidisciplinary oncological consultation where the treatment plan for newly diagnosed cancers is discussed and decided (MOC/COM report).

2.1.1 Skull base chondrosarcoma

Chondrosarcomas are uncommon malignant neoplasms of the cartilage; only 1% of chondrosarcomas arise in the skull base²¹. Chondrosarcomas are rare in children; when they occur, they tend to be aggressive²². The complete surgical resection of these tumours is most often prevented by their deep location; consequently, a combination of surgery and irradiation has become the mainstay of treatment²³.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): <1/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 0
Evidence base PBT	1 retrospective case series (n=7)
Conclusion	At present insufficient scientific evidence to support or to refute

^c Data provided by the Belgian Cancer Registry. Cave: for some tumour types the indications under study were slightly redefined. Second, some selection criteria were overlapping, resulting in double recordings of some patients. For more details the reader is referred to the Scientific Report.

^d Data provided by the Belgian Cancer Registry.



2.1.2 Skull base & (para)spinal chordoma

Chordomas are extra-axial tumours that originate from the remnants of the notochord. Chordomas rarely affect children and adolescents²⁴. In children and adolescents surgery is rarely curative because of the difficulty to obtain clear margins and the likelihood of chordomas to arise in the skull base, where they are relatively inaccessible to complete surgical excision²⁵. Tumour tissue that remains after surgery, particularly when small in volume, can be managed effectively with radiotherapy²⁴.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): <1/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): NA
Evidence base PBT	2 retrospective case series (n=41)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.3 Craniopharyngioma

Craniopharyngiomas are relatively rare intracranial tumours, with a peak incidence occurring at 5-14 years of age²⁶. Despite their histologically benign nature, craniopharyngiomas frequently cause profound disabilities due to their proximity to critical structures such as the optic pathway, cerebral arteries, the hypothalamus, the pituitary gland, cranial nerves and the brain parenchyma^{26-28,29}. There is no consensus on the optimal treatment of newly diagnosed craniopharyngiomas, but surgery and radiotherapy are the cornerstones in their management³⁰. Regardless of the treatment modality, 5- and 10-year overall survival rates in children are greater than 90%³¹.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 3/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 1/year
Evidence base PBT	1 retrospective comparative study & 2 retrospective case series (n=74)
Conclusion	At present very low level scientific evidence that PBT compared with IMRT does not result in significant differences in 3-yr OS, 3-yr CFFS, 3-yr NFFS, toxicity or cyst dynamics.

OS: overall survival; CFFS: cystic failure-free survival; NFFS: nodular failure-free survival



2.1.4 Ependymoma

Ependymomas are one of the three types of gliomas, tumours of the supporting tissue of the brain. In children, most ependymomas arise in or around the fourth ventricle³². One third of cases are diagnosed under the age of three years and the vast majority by age six years⁸. Standard treatment for all grades and ages includes maximal surgical resection and adjuvant radiotherapy³³. For children aged 0-19 years with ependymoma, the overall 5-year relative survival rate is 72.1%³⁴.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 6/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 4/year
Evidence base PBT	1 prospective case series & 1 retrospective case series (n=78)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.5 Esthesioneuroblastoma

Esthesioneuroblastoma, also known as olfactory neuroblastoma, is an uncommon malignancy of neural crest origin^{35, 36}. The behaviour of the tumour varies from an indolent slow-growing neoplasm to that of a highly aggressive and locally invasive malignancy with a capacity for regional and distant metastases³⁷. Approximately 7% to 20% of patients present at the age of 10 to 24 y.o.³⁵. Surgery and adjuvant radiation therapy have been the mainstay of treatment. Chemotherapy has also been used in combination with surgery and radiation therapy³⁷. Estimated 5-year overall survival rates are 73% for surgery and radiotherapy, 68% for surgery only, 35% for radiotherapy only, and 26% for neither surgery nor radiotherapy³⁸.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): <1/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): <1/year
Evidence base PBT	1 retrospective case series (n=22 ^e)
Conclusion	At present insufficient scientific evidence to support or to refute

^e Mixture of children and adults



2.1.6 Ewing sarcoma

Ewing sarcomas are derived from primordial bone marrow-derived mesenchymal stem cells. They arise mainly in bone and infrequently in soft tissues³⁹. The median age of patients with Ewing sarcoma is 15 years³⁹. Current treatment consists of a multimodal approach combining surgery, radiotherapy and chemotherapy^{40, 41}. Between 1975 and 2002, the 5-year overall survival rate has increased from 59% to 76% for children (<15 y.o.) and from 20% to 49% for adolescents (15-19 y.o.)³⁹. Patients with metastatic disease (i.e. 1 out of 4) achieve a 6-year event-free survival of approximately 28% and an overall survival of approximately 30%³⁹.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 8/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 3/year
Evidence base PBT	1 retrospective case series (n=30)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.7 CNS germinoma

Central nervous system (CNS) germ cell tumours generally affect adolescents⁴². Two types have been identified: germinomas, which are the most common and carry the most favourable prognosis, and mixed malignant germ cell tumours (also termed non-germinomatous germ cell tumours), which are relatively resistant to therapy⁴³. Germinomas are highly radiosensitive and have been traditionally treated with radiation therapy alone. Craniospinal irradiation with a boost to the region of the primary tumour has resulted in 5-year overall survival rates greater than 90%⁴⁴.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 2/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 2/year
Evidence base PBT	1 retrospective case series (n=22)
Conclusion	At present insufficient scientific evidence to support or to refute



2.1.8 Low-grade glioma (incl. optic pathway)

Any tumour that arises from glial cells is a glioma. Low-grade gliomas are the most common paediatric brain tumour, representing over 30% of all childhood primary brain tumours⁴⁵. Low-grade gliomas are frequently amenable to surgical resection⁴⁶. Yet, when the risk of post-surgical morbidity is considered too high chemotherapy may be the first line of treatment for children under 7-10 years of age. Radiation therapy is used when tumours progress after chemotherapy or in older children⁴⁶.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 47/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 9/year
Evidence base PBT	2 retrospective case series (n=38)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.9 Medulloblastoma / primitive neuroectodermal tumours

Medulloblastomas and primitive neuroectodermal tumours (PNET) are embryonal tumours, which share the tendency to disseminate throughout the nervous system⁴⁷. They occur throughout the paediatric age spectrum, but tend to cluster early in life⁴⁷. Surgical resection is the mainstay of therapy for all medulloblastoma/PNET. Due to the high metastatic tendency within the CNS, all patients receive “prophylactic” craniospinal irradiation (CSI) for elimination of invisible micrometastases. The 5-year overall survival for children with standard risk medulloblastoma is 75 – 85%⁴⁸. In the subset of children younger than 5 y.o. long-term disease control is far worse (e.g. ranging from 14% to 55% depending on tumour histology⁴⁹), although others reported five-year progression-free and overall survival rates of 85±8% and 95±5%, respectively, in children younger than 3 y.o. with desmoplastic medulloblastoma⁵⁰. Paediatric PNETs carry an even more dismal prognosis: the 5-year overall survival ranges between 30 and 40%⁴⁹.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 12/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 9/year
Evidence base PBT medulloblastoma	1 prospective case series & 2 retrospective case series (n=147 ^f)
Evidence base PBT PNET	None
Conclusion medulloblastoma	At present insufficient scientific evidence to support or to refute
Conclusion PNET	At present no scientific evidence to support or to refute

^f This is an overestimation as some cases may have been reported in 2 publications.



2.1.10 Non-resectable osteosarcoma

Osteosarcoma is an aggressive, malignant bone-forming mesenchymal tumour, predominantly affecting the long bones of adolescents and young adults. Aggressive local growth and rapid haematogenous systemic dissemination are typical features. Successful treatment generally requires the combination of effective systemic chemotherapy and complete resection of all clinically detectable disease. Osteosarcomas are generally considered to be radioresistant⁵¹, but when complete surgical resection is not possible radiotherapy may be an option to try to extend the progression-free interval⁵². Local control of the tumour is absolutely critical, because the chances of long term survival are <10% if a complete surgical resection of the tumour is not possible⁵³.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 9/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): <1/year
Evidence base PBT	1 retrospective case series (n=55 ^e)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.11 Pelvic sarcomas

Treatment of malignant sarcomas of the pelvis poses a challenge for local disease control and oncologic outcome⁵⁴. Surgical resection is difficult because of the anatomic proximity to many neurovascular structures and the urinary and intestinal tracts and because extensive resection of pelvic sarcomas often necessitates reconstruction to avoid severe functional disabilities from the impairment of the load-bearing axis⁵⁵. At present, there is no consensus yet whether a uniform treatment strategy should be applied to all patients regardless of the histopathology⁵⁴. Evaluation of the SEER⁹ database revealed a 5-year overall survival of 47% with osteosarcoma having the worst 5-year survival at 19% and patients with chordoma having the best 5-year survival at 60%⁵⁴.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 6/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 2/year
Evidence base PBT	None
Conclusion	At present no scientific evidence to support or to refute

⁹ The Surveillance, Epidemiology and End Results (SEER) database provides population-based incidence and survival data for primary malignant tumours collected from 17 registries in the United States.



2.1.12 Pineal parenchymal tumours

Tumours originating from the pineal region are very rare; they account for less than 1% of all primary central nervous system tumours⁵⁶. Pineal parenchymal tumours represent about 10-30% of all tumours in the pineal region⁵⁷. Treatment may consist of surgery, radiotherapy and/or chemotherapy. In general, survival of patients with pineal parenchymal tumours is considered much more doubtful compared to that of patients with other pineal region tumours. Evaluation of the SEER⁹ database revealed a 5-year overall survival of 47.2% and a median survival of 4.5 years⁵⁶.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): <1/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 0/year
Evidence base PBT	None
Conclusion	At present no scientific evidence to support or to refute

2.1.13 Retinoblastoma

Retinoblastoma is a relatively uncommon tumour of childhood that arises in the retina; 95% of cases are diagnosed before age 5 years, and two-thirds of these cases occur before age 2 years. Due to the radiosensitive nature of retinoblastomas, external beam radiation therapy (EBRT) has been thought to be the first line and major treatment method for retinoblastoma⁵⁸. However, EBRT may result in orbital bone growth retardation and consequent cosmetic problems, particularly in younger children. Therefore, treatment modalities were shifted toward primary systemic chemotherapy for reducing tumour volume initially (chemo reduction) and additional focal treatment such as cryotherapy, thermotherapy, or brachytherapy⁵⁸. According to estimates based on the SEER⁹ database current 5-year survival rate may be as high as 96.5% (1995–2004)⁵⁹.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 12/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 1/year
Evidence base PBT	1 retrospective comparative study (n=55)
Conclusion	At present there is very low level scientific evidence that PBT results in lower risk of developing RT-induced in-field secondary malignancies. However, since radiation-induced solid malignancies need at least 5 to 10 years to develop and for some children in the study the follow-up was short, the results should be interpreted with caution .



2.1.14 Rhabdomyosarcoma

Rhabdomyosarcomas are malignancies of mesenchymal cell origin that arise primarily in striated muscle tissues^{8, 60}. In children, the most common primary sites are the orbit (i.e. 35-45% of all childhood rhabdomyosarcoma)⁶¹ and the genito-urinary tract⁶². There is a bimodal incidence distribution with a first peak at 6 y.o. and a second peak at adolescence⁸. Rhabdomyosarcomas require a multidisciplinary approach including surgery, chemotherapy and radiotherapy⁶³. Prognosis depends on the histologic type and the tumour site⁶³. The overall impression is that survival for most patient subsets is superior with the use of early local therapy, including RT⁶².

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 9/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): 4/year
Evidence base PBT	3 retrospective case series (n=36)
Conclusion	At present insufficient scientific evidence to support or to refute

2.1.15 (Para-)spinal 'adult type' soft tissue sarcoma (STS)

The most common STS in children younger than 15 y.o. is rhabdomyosarcoma; the remaining soft tissue sarcomas are commonly referred to as non-rhabdomyosarcomatous STS and account for about 3% of all childhood tumours. The latter are characterized by local aggressiveness and a propensity to metastasize that is correlated to their grade of malignancy⁶⁴. Radiotherapy plays a dominant role in those tumours which cannot be surgically removed without leading to major impairment, yet, it may cause severe late side effects. Five year overall survival in children and adolescents with non-rhabdomyosarcomatous STS may be as high as 89% in patients who underwent complete resection at diagnosis, 79% in patients with marginal resection, 52% in initially unresected patients and 17% in patients with metastases at onset⁶⁴.

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): <1/year
Eligible for RT/PBT (estimate)^d	Children (0-14 y.o.): <1/year
Evidence base PBT	None
Conclusion	At present no scientific evidence to support or to refute



2.2 Clinical effectiveness of carbon ion radiotherapy and eligibility for radiotherapy/carbon ion radiotherapy

Non-resectable osteosarcoma

(For the pathology description, the reader is referred to paragraph 0)

Incidence in Belgium (2004-11)^c	Children (0-14 y.o.): 9/year
Eligible for RT/CIRT (estimate)^d	Children (0-14 y.o.): <1/year
Evidence base CIRT	1 retrospective case series (n=78 ^e)
Conclusion	At present insufficient scientific evidence to support or to refute

3 DISCUSSION

Due to its physical properties, proton therapy spares more normal tissues and organs at risk than conventional radiotherapy. Because a reduction of radiation dose to the healthy tissue is the goal of radioprotection, it is conceivable that a decrease of radiation dose to vulnerable tissues by using protons will decrease important side effects and radiation-induced cancers as well.

Worldwide a growing number of children is being treated with proton beam therapy (PBT). Yet, we have no Belgian data and a European registry has not been installed yet. A survey among all American proton centres showed that in 2012 a total of 694 paediatric patients were treated⁵. The six most common tumour types treated were ependymoma, medulloblastoma, low-grade glioma, rhabdomyosarcoma, Ewing sarcoma, and craniopharyngioma⁵; indications for which we found either no or insufficient scientific evidence to support or to refute proton beam therapy.

It is appalling that **only a fraction of children treated with PBT are enrolled in clinical trials⁶⁵**. There may be several reasons for that, including the fact that many clinicians are convinced that the superior dose distribution and lower integral dose makes proton beam therapy the preferred treatment option, and thus making them reluctant to randomize patients. Furthermore, long-term follow-up, crucial to assess late side effects as well as secondary cancer risk, may be difficult when patients come from large distances or from abroad and will take over a decade.

While multicentre studies are definitely the only possible way to get more data on the clinical effectiveness of proton beam therapy, the (international) collaboration between centres is not going without a hitch. In fact, there seems to be some competition between them and funding for this type of research is also lacking.

In the medical literature animated debates have been held on the necessity or ethical justification of randomized controlled trials to test proton beam therapy⁶⁶⁻⁶⁹. Given the fact that systematic reviews fail to demonstrate clear evidence of a clinical superiority for protons, it is difficult to understand why it would be unethical to perform randomized trials^{67, 69}, except in those cases where there are manifest anatomical and physical reasons against the use of photons (e.g. low-grade glioma, craniopharyngioma, skull base chordoma and skull base osteosarcoma). Most certainly, for prevalent indications (e.g.



in adults), there should be no discussion on the necessity of proving PBT's superiority and cost-effectiveness through randomized clinical trials.

For children (and for adults with rare cancers), some mitigating factors may apply: in addition to the factors mentioned before, the number of children with cancer requiring radiotherapy as part of their treatment is so small that it is unlikely that prospective randomized trials can be conducted to test if different dose distributions indeed make a clinical difference⁷⁰.

Furthermore, as was pointed out earlier, the clinical application of proton beam therapy still has to contend with **serious technical limitations and disadvantages**: the magnitude of the lateral penumbra, the uncertainty about the distal edge degradation, range inaccuracies, patient-position related uncertainties, operational difficulties and last but not least cost-effectiveness issues. With an extra cost of 70% to 150%^{71, 72}, the payer - whether public or private - deserves to know how much better the outcomes are.

As the treatment of children demands **specific skills and precautions** (e.g. anaesthesia is required in nearly half of the children⁵), the concentration of children in a restricted number of centres should be mandatory. **Quality assurance** is another important aspect not to be neglected. Yet, high quality can only be delivered if the operators have sufficient time; economic pressure to increase the throughput of the machine should never prevail. The protocols being developed by the Particle Therapy Co-Operative Group (PTCOG)^h are an important initiative in that respect.

Prospective comparative clinical trials in the field are urgently needed. In addition, the establishment of a **European Hadron Therapy Registry** (EHTR), which holds (anonymised) data on patients treated by European hadron centres would provide a simple but effective solution to the current lack of coherent published data⁷³. In the US the Pediatric Proton Consortium Registry (PPCR) was recently installed for that purpose⁷⁴.

4 KEY MESSAGES

- **Based on the 2004-2011 incidence data, it can be estimated that in Belgium 37 children (0-14 y.o.) and 14 adolescents (15-19 y.o.) may be eligible for RT/PBT on a yearly basis.**
- **The use of PBT in children is supported by physical data showing an important reduction of the radiation dose to normal tissues. Yet, to date clinical data on PBT in all paediatric cancers under study is lacking critical information on measures of long-term effectiveness and harm.**

^h <http://www.ptcog.ch/index.php/clinical-protocols>



RECOMMENDATIONSⁱ

To the clinicians:

- Patients (or their parents or representatives) should be fully informed that despite the physical underpinning of proton beam therapy, its clinical efficacy for the indications considered in this report has not yet been confirmed in clinical studies.
- Children should be referred to proton beam centres with the necessary expertise in treating children with that specific pathology and involved in clinical studies with long-term follow-up (if recruiting in Europe).
- The registration in the Belgian Cancer Registry (BCR) database of the chemotherapy regimen and radiotherapy schedule (including hadron therapy) administered in children is recommended. This registration can allow, amongst others, the monitoring of secondary malignancies occurrence.

To the Technical Medical Council & the Insurance Committee of the RIZIV - INAMI:

- The current reimbursement for PBT should be reevaluated periodically as new scientific evidence on effectiveness and safety becomes available. Meanwhile, the 15-year age limit should be reconsidered for certain indications.
- The amount reimbursed for radiotherapy in children should take into account the complexity of treatment administration, including the potential need for anaesthesia. The reimbursement should be made conditional to the registration into the BCR database.

To the RIZIV - INAMI, BCR & FANC - AFCN and scientific/professional associations:

- Our country should actively promote the set-up of a European Hadron Therapy Registry.

Research agenda:

- There is an urgent need for more research, not only on the clinical efficacy, side effects, and harms, but also on the economical aspects, and on the physics and biology. Clinical research should preferentially be conducted in an internationally coordinated way.

ⁱ The KCE has sole responsibility for the recommendations.



■ REFERENCES

1. Huybrechts M, Obyn C, Gailly J, Mambourg F, Vinck I, Ramaekers D. Hadrontherapy (Structured abstract). Health Technology Assessment Database. 2007(1).
2. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol.* 2013;66(2):151-7.
3. Annemans L, Colardyn F, De Croock R, De Neve W, Duprez F, Gulyban A, et al. Feasibility study of a Hadron therapy centre in Belgium. Brussels: 2013.
4. Jermann M. Particle therapy statistics in 2013. *International Journal of Particle Therapy.* 2014;1(1):4.
5. Chang AL, Yock TI, Mahajan A, Hill-Kaiser C, Keole S, Loreda L, et al. Pediatric proton therapy: patterns of care across the United States. *International Journal of Particle Therapy.* 2014;1(2):11.
6. Larsson B, Leksell L, Rexed B, Sourander P, Mair W, Andersson B. The high-energy proton beam as a neurosurgical tool. *Nature.* 1958;182(4644):1222-3.
7. Terasawa T, Dvorak T, Ip S, Raman G, Lau J, Trikalinos TA. Systematic review: Charged-particle radiation therapy for cancer. *Ann. Intern. Med.* 2009;151(8):556-65.
8. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. *Technol. Cancer Res. Treat.* 2012;11(3):267-78.
9. Timmermann B. Proton beam therapy for childhood malignancies: Status report. *Klin. Padiatr.* 2010;222(3):127-33.
10. Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: a charged issue. *Radiother Oncol.* 2008;86(2):165-70.
11. Amsbaugh MJ, Zhu XR, Palmer M, Poenisch F, McAleer MF, Mahajan A, et al. Spot scanning proton therapy for craniopharyngioma. *Pract. Radiat. Oncol.* 2012;2(4):314-8.
12. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *Int J Radiat Oncol Biol Phys.* 2006;65(1):1-7.
13. Islam MR, Collums TL, Zheng Y, Monson J, Benton ER. Off-axis dose equivalent due to secondary neutrons from uniform scanning



- proton beams during proton radiotherapy. *Phys Med Biol.* 2013;58(22):8235-51.
14. Zheng Y, Liu Y, Zeidan O, Schreuder AN, Keole S. Measurements of neutron dose equivalent for a proton therapy center using uniform scanning proton beams. *Med Phys.* 2012;39(6):3484-92.
 15. Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. *Int J Radiat Oncol Biol Phys.* 2013;87(1):10-2.
 16. Olsen DR, Bruland OS, Frykholm G, Norderhaug IN. Proton therapy - a systematic review of clinical effectiveness. *Radiother Oncol.* 2007;83(2):123-32.
 17. Brada M, Pijls-Johannesma M, De Ruyscher D. Current clinical evidence for proton therapy. *Cancer J.* 2009;15(4):319-24.
 18. Ramaekers BL, Pijls-Johannesma M, Joore MA, Ende P, Langendijk JA, Lambin P, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons (Structured abstract). *Cancer Treatment Reviews.* 2011;37(3):185-201.
 19. De Ruyscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, et al. Charged particles in radiotherapy: a 5-year update of a systematic review. *Radiother Oncol.* 2012;103(1):5-7.
 20. Measurements. NCoRP. The Relative Biological Effectiveness of Radiations of Different Quality - Report 104. 1990.
 21. Bloch O, Parsa AT. Skull Base Chondrosarcoma. Evidence-Based Treatment Paradigms. *Neurosurg. Clin. North Am.* 2013;24(1):89-96.
 22. Mavrogenis AF, Gambaroti M, Angelini A, Palmerini E, Staals EL, Ruggieri P, et al. Chondrosarcomas revisited. *Orthopedics.* 2012;35(3):e379-e90.
 23. Bloch OG, Jian BJ, Yang I, Han SJ, Aranda D, Ahn BJ, et al. A systematic review of intracranial chondrosarcoma and survival. *J Clin Neurosci.* 2009;16(12):1547-51.
 24. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: Current concepts, management, and future directions. *Lancet Oncol.* 2012;13(2):e69-e76.
 25. National Cancer Institute. Other Rare Unusual Cancers of Childhood [Web page]. National Institutes of Health 2014 [updated 2014-08-10; cited 2014-07-11]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/unusual-cancers-childhood/patient/page7>
 26. Iannalfi A, Fragkandrea I, Brock J, Saran F. Radiotherapy in craniopharyngiomas. *Clin. Oncol.* 2013;25(11):654-67.
 27. Laffond C, Dellatolas G, Alapetite C, Puget S, Grill J, Habrand JL, et al. Quality-of-life, mood and executive functioning after childhood craniopharyngioma treated with surgery and proton beam therapy. *Brain Inj.* 2012;26(3):270-81.
 28. Muller HL. Childhood craniopharyngioma. *Pituitary.* 2013;16(1):56-67.
 29. Luu QT, Loredó LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. *Cancer Journal.* 2006;12(2):155-9.
 30. Kortmann RD. Different approaches in radiation therapy of craniopharyngioma. *Frontiers in Endocrinology.* 2011;2(100).
 31. National Cancer Institute. Childhood Craniopharyngioma Treatment [Web page]. National Institutes of Health;2014 [updated 2014-08-12; cited 2014-07-11]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/child-cranio/healthprofessional>
 32. National Cancer Institute. General Information About Childhood Ependymoma [Web page]. National Institutes of Health 2014 [updated 2014-07-10; cited 2014-08-14]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/childependymoma/Patient>
 33. Wright KD, Gajjar A. Current treatment options for pediatric and adult patients with ependymoma. *Curr. Treat. Options Oncol.* 2012;13(4):465-77.
 34. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision). 2012. Available from: www.cbtrus.org



35. Mahooti S, Wakely PE, Jr. Cytopathologic features of olfactory neuroblastoma. *Cancer*. 2006;108(2):86-92.
36. Soler ZM, Smith TL. Endoscopic versus open craniofacial resection of esthesioneuroblastoma: what is the evidence? *Laryngoscope*. 2012;122(2):244-5.
37. Bak M, Wein RO. Esthesioneuroblastoma: a contemporary review of diagnosis and management. *Hematol Oncol Clin North Am*. 2012;26(6):1185-207.
38. Platek ME, Merzianu M Fau - Mashtare TL, Mashtare TI Fau - Popat SR, Popat Sr Fau - Rigual NR, Rigual Nr Fau - Warren GW, Warren Gw Fau - Singh AK, et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. *Radiat Oncol*. 2011;6(41):6-41.
39. National Cancer Institute. Ewing Sarcoma Treatment [Web page]. National Institutes of Health 2014 [updated 2014-08-15; cited 2014-08-14]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/ewings/HealthProfessional>
40. Gray ST, Chen YL, Lin DT. Efficacy of proton beam therapy in the treatment of ewing's sarcoma of the paranasal sinuses and anterior skull base. *Skull Base*. 2009;19(6):409-16.
41. Iwata S, Yonemoto T, Ishii T, Kumagai K, Imai R, Hagiwara Y, et al. Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing's sarcoma family of tumors. *Int J Clin Oncol*. 2013;18(6):1114-8.
42. MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: Early clinical outcomes. *Int. J. Radiat. Oncol. Biol. Phys*. 2011;79(1):121-9.
43. Robertson PL, Jakacki R, Hukin J, Siffert J, Allen JC. Multimodality therapy for CNS mixed malignant germ cell tumors (MMGCT): results of a phase II multi-institutional study. *J Neurooncol*. 2014;118(1):93-100.
44. National Cancer Institute. Childhood Central Nervous System Germ Cell Tumors Treatment [Web page]. National Institutes of Health 2014 [updated 2014-08-14; cited 2014-05-09]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/childCNS-germ-cell/healthprofessional>
45. Minturn JE, Fisher MJ. Gliomas in children. *Curr. Treat. Options Neurol*. 2013;15(3):316-27.
46. Rombi B MS, Maurizio A, Tarbell NJ, Yock TI. Proton Radiotherapy for Childhood Tumors: an Overview of Early Clinical Results. *Nucl Med radiat Ther*. 2013;4(4):1-9.
47. National Cancer Institute. Childhood Central Nervous System Embryonal Tumors Treatment [Web page]. National Institutes of Health 2014 [updated 2014-05-02; cited 2014-08-07]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/childCNSEmbryonal/healthprofessional>
48. Brodin NP, Munck Af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. *Acta Oncol*. 2011;50(6):806-16.
49. Jimenez RB, Sethi R, Depauw N, Pulsifer MB, Adams J, McBride SM, et al. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: Outcomes for very young children treated with upfront chemotherapy. *Int. J. Radiat. Oncol. Biol. Phys*. 2013;87(1):120-6.
50. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. *N Engl J Med*. 2005;352(10):978-86.
51. Oya N, Kokubo M, Mizowaki T, Shibamoto Y, Nagata Y, Sasai K, et al. Definitive intraoperative very high-dose radiotherapy for localized osteosarcoma in the extremities. *Int J Radiat Oncol Biol Phys*. 2001;51(1):87-93.
52. Group EESNW, Blay J-Y, Blomqvist C, Bonvalot S, Boukovinas I, Casali PG, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7:vii100-9.
53. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, et al. Non-randomized therapy trial to determine the



- safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. *BMC Cancer*. 2010;10.
54. Jawad MU, Haleem AA, Scully SP. Malignant sarcoma of the pelvic bones: treatment outcomes and prognostic factors vary by histopathology. *Cancer*. 2011;117(7):1529-41.
55. Han I, Lee YM, Cho HS, Oh JH, Lee SH, Kim H-S. Outcome after surgical treatment of pelvic sarcomas. *Clin Orthop Surg*. 2010;2(3):160-6.
56. Al-Hussaini M, Sultan I, Abuirmileh N, Jaradat I, Qaddoumi I. Pineal gland tumors: experience from the SEER database. *J Neurooncol*. 2009;94(3):351-8.
57. Stoiber EM, Schaible B, Herfarth K, Schulz-Ertner D, Huber PE, Debus J, et al. Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003--a single institution's experience. *Radiat Oncol*. 2010;5:122.
58. Chang JW, Yu YS, Kim JY, Shin DH, Choi J, Kim JH, et al. The clinical outcomes of proton beam radiation therapy for retinoblastomas that were resistant to chemotherapy and focal treatment. *Korean J Ophthalmol*. 2011;25(6):387-93.
59. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. *Br J Ophthalmol*. 2009;93(1):24-7.
60. Punyko JA MA, Baker KS, Ness KK, Robison LL, Gurney JG. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. *Cancer* 2005;103(7):1475-83.
61. Ge X, Huang DS, Shi JT, Ma JM. Multidisciplinary collaborative therapy for 30 children with orbital rhabdomyosarcoma. *Asian Pac J Cancer Prev*. 2013;14(8):4641-6.
62. National Cancer Institute. Childhood Rhabdomyosarcoma Treatment [Web page]. National Institutes of Health 2014 [updated 2014-08-19; cited 2014-06-13]. Available from: <http://www.cancer.gov/cancertopics/pdq/treatment/childrhabdomyosarcoma/HealthProfessional>
63. Jurdy L, Merks JHM, Pieters BR, Mourits MP, Kloos RJHM, Strackee SD, et al. Orbital rhabdomyosarcomas: A review. *Saudi J Ophthalmol*. 2013;27(3):167-75.
64. Ferrari A, Casanova M, Collini P, Meazza C, Luksch R, Massimino M, et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol*. 2005;23(18):4021-30.
65. Merchant TE. Clinical controversies: Proton therapy for pediatric tumors. *Semin. Radiat. Oncol*. 2013;23(2):97-108.
66. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? *J Clin Oncol*. 2008;26(2):175-6.
67. Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized clinical trials be required for proton radiotherapy? An alternative view. *J Clin Oncol*. 2008;26(15):2438-9.
68. Tepper JE. Protons and parachutes. *J Clin Oncol*. 2008;26(15):2436-7.
69. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. *J Clin Oncol*. 2008;26(15):2590-1; author reply 3-6.
70. Halperin EC. Randomized prospective trials of innovative radiotherapy technology are necessary. *J Am Coll Radiol*. 2009;6(1):33-7.
71. Lievens Y, Van den Bogaert W. Proton beam therapy: too expensive to become true? *Radiother Oncol*. 2005;75(2):131-3.
72. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. *Clin Oncol (R Coll Radiol)*. 2003;15(1):S37-50.
73. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruyscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer>. *Radiother. Oncol*. 2007;83(2):110-22.
74. Kasper HBR, L.; Indelicato, D.J.; Symecko, H.; Hartsell, W.; Mahajan, A.; Hill-Kayser, C.; Perkins, S.M.; Chang, A.L.; Childs, S.; Buchsbaum, J.C.; Laurie, F.; Khan, A.J.; Giraud, C.; Yeap, B.Y.; Yock, T.I. The Pediatric Proton Consortium Registry: A Multi-institutional Collaboration in U.S. Proton Centers. *International Journal of Particle Therapy*. 2014;1(2):11.

